Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2025
Biochemistry, Genetics and Molecular Biology journal rankings 2025
1,367 ranked journals · Field in Life Sciences
Biochemistry, Genetics and Molecular Biology has 1,367 ranked journals in 2025. The median journal has an OJR of 0.87, below the world average of 1.00, up 0.02 on 2024; Q1 starts at OJR 1.35. The three highest-scoring journals with stable ranks are Signal Transduction and Targeted Therapy, Cell, and Molecular Cancer: each is likely ranked within the top 14.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Biochemistry, Genetics and Molecular Biology (14)
Up to Life Sciences1,367 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #1 of 1,367Signal Transduction and Targeted TherapyOASpringer Nature · United Kingdom | 14.09Q1 | 55.38 21.43 up from 2024 | 1,202 | 100% | $3,790 | Rising vs field, 2022–25 | |
Rank 2; likely between #2 and #4 of 1,367CellCell Press · United States | 10.00Q1 | 36.19 2.51 up from 2024 | 1,416 | 79% | $11,400 | ||
Rank 3; likely between #2 and #5 of 1,367Molecular CancerOABioMed Central · United Kingdom | 9.39Q1 | 38.06 2.29 up from 2024 | 632 | 100% | $5,090 | ||
Rank 4; likely between #3 and #6 of 1,367Cell MetabolismCell Press · United States | 8.52Q1 | 29.24 5.30 up from 2024 | 566 | 58% | $10,400 | Rising vs field, 2022–25 | |
Rank 5; likely between #2 and #14 of 1,367iMetaOAWiley · Australia | 8.16Q1 | 25.45 1.05 up from 2024 | 236 | 100% | $1,320 | ||
Rank 6; likely between #5 and #9 of 1,367ScienceAmerican Association for the Advancement of Science · United States | 7.42Q1 | 22.44 0.97 up from 2024 | 4,951 | 28% | — | Rising vs field, 2022–25 | |
Rank 7; likely between #4 and #12 of 1,367Nature Reviews Molecular Cell BiologyNature Portfolio · United Kingdom | 7.27Q1 | 49.49 9.94 up from 2024 | 346 | 26% | — | ||
Rank 8; likely between #5 and #15 of 1,367Nature Reviews MicrobiologyNature Portfolio · United Kingdom | 6.92Q1 | 38.79 2.35 up from 2024 | 443 | 20% | — | Rising vs field, 2022–25 | |
Rank 9; likely between #7 and #12 of 1,367NatureNature Portfolio · United Kingdom | 6.63Q1 | 21.72 2.93 up from 2024 | 9,958 | 35% | $12,690 | ||
Rank 10; likely between #5 and #21 of 1,367Fungal DiversitySpringer Science+Business Media · Netherlands | 6.46Q1 | 21.31 1.84 up from 2024 | 45 | 33% | $3,490 | ||
Rank 11; likely between #7 and #21 of 1,367Bone ResearchOASpringer Nature · China | 6.07Q1 | 20.61 3.93 up from 2024 | 188 | 100% | $3,405 | Rising vs field, 2022–25 | |
Rank 12; likely between #10 and #22 of 1,367Nature Biomedical EngineeringNature Portfolio · United Kingdom | 5.61Q1 | 19.03 1.95 down from 2024 | 478 | 54% | $12,690 | Rising vs field, 2022–25 | |
Rank 13; likely between #8 and #32 of 1,367Military Medical ResearchOABioMed Central · China | 5.59Q1 | 19.24 0.37 up from 2024 | 219 | 100% | $0 listed | ||
Rank 14; likely between #8 and #44 of 1,367Progress in Lipid ResearchElsevier BV · United Kingdom | 5.42Q1 | 18.89 1.71 up from 2024 | 80 | 71% | $5,530 | ||
Rank 15; likely between #11 and #25 of 1,367Nature GeneticsNature Portfolio · United States | 5.36Q1 | 15.99 3.99 down from 2024 | 950 | 60% | $12,690 | Falling vs field, 2022–25 | |
Rank 16; likely between #10 and #33 of 1,367Drug Resistance UpdatesElsevier BV · United Kingdom | 5.30Q1 | 19.76 2.19 down from 2024 | 223 | 40% | $5,410 | ||
Rank 17; likely between #8 and #46 of 1,367International Journal of Oral ScienceOASpringer Nature · China | 5.26Q1 | 19.32 5.11 up from 2024 | 171 | 100% | $3,890 | ||
Rank 18; likely between #10 and #41 of 1,367Pharmacological ReviewsAmerican Society for Pharmacology and Experimental Therapeutics · United States | 5.25Q1 | 15.16 3.73 down from 2024 | 147 | 67% | $4,500 | ||
Rank 19; likely between #11 and #35 of 1,367Nature BiotechnologyNature Portfolio · United States | 5.19Q1 | 19.55 0.54 down from 2024 | 1,081 | 30% | $12,690 | Falling vs field, 2022–25 | |
Rank 20; likely between #12 and #41 of 1,367Nature ProtocolsNature Portfolio · United States | 4.93Q1 | 19.00 1.44 up from 2024 | 434 | 37% | — | ||
Rank 21; likely between #17 and #30 of 1,367Science Translational MedicineAmerican Association for the Advancement of Science · United States | 4.88Q1 | 15.49 0.51 up from 2024 | 895 | 45% | — | Rising vs field, 2022–25 | |
Rank 22; likely between #17 and #34 of 1,367Nature MicrobiologyNature Portfolio · United Kingdom | 4.83Q1 | 14.17 0.85 down from 2024 | 785 | 61% | $12,690 | ||
Rank 23; likely between #21 and #29 of 1,367Nature CommunicationsOANature Portfolio · United Kingdom | 4.77Q1 | 18.80 1.77 up from 2024 | 26,176 | 100% | $6,990 | ||
Rank 24; likely between #16 and #39 of 1,367Circulation ResearchLippincott Williams & Wilkins · United States | 4.76Q1 | 13.25 0.73 down from 2024 | 672 | 22% | — | ||
Rank 25; likely between #15 and #39 of 1,367Nature MetabolismNature Portfolio · United Kingdom | 4.76Q1 | 17.55 3.16 up from 2024 | 616 | 54% | $12,690 | ||
Rank 26; likely between #15 and #49 of 1,367Nature reviews. CancerNature Portfolio · United Kingdom | 4.66Q1 | 24.85 3.56 down from 2024 | 339 | 22% | — | ||
Rank 27; likely between #17 and #44 of 1,367Experimental & Molecular MedicineOASpringer Nature · South Korea | 4.57Q1 | 17.90 3.67 up from 2024 | 618 | 100% | $4,490 | Rising vs field, 2022–25 | |
Rank 28; likely between #13 and #59 of 1,367FEMS Microbiology ReviewsOAOxford University Press · Netherlands | 4.53Q1 | 19.47 8.17 up from 2024 | 147 | 100% | $3,297 | Rising vs field, 2022–25 | |
Rank 29; likely between #9 and #100 of 1,367npj Antimicrobials and ResistanceOASpringer Science+Business Media | 4.50Q1 | 15.15 4.62 up from 2024 | 68 | 100% | $3,190 | ||
Rank 30; likely between #9 and #71 of 1,367Journal of Extracellular VesiclesOATaylor & Francis · United States | 4.46Q1 | 21.41 6.58 up from 2024 | 347 | 100% | $4,410 | ||
Rank 31; likely between #15 and #57 of 1,367Nature MethodsNature Portfolio · United States | 4.44Q1 | 15.53 1.33 down from 2024 | 1,124 | 49% | $12,690 | ||
Rank 32; likely between #24 and #43 of 1,367MicrobiomeOABioMed Central · United Kingdom | 4.42Q1 | 15.39 1.39 up from 2024 | 759 | 100% | $4,990 | ||
Rank 33; likely between #25 and #42 of 1,367Redox BiologyOAElsevier BV · Netherlands | 4.39Q1 | 16.43 3.67 up from 2024 | 1,168 | 100% | $4,310 | Rising vs field, 2022–25 | |
Rank 34; likely between #21 and #50 of 1,367Cell Host & MicrobeCell Press · United States | 4.38Q1 | 15.62 3.23 up from 2024 | 628 | 54% | $10,400 | ||
Rank 35; likely between #22 and #49 of 1,367Cell stem cellElsevier BV · United States | 4.35Q1 | 15.98 1.95 up from 2024 | 472 | 61% | $10,400 | ||
Rank 36; likely between #17 and #60 of 1,367Molecular Aspects of MedicineElsevier BV · United Kingdom | 4.29Q1 | 15.43 3.46 up from 2024 | 133 | 38% | $5,220 | Rising vs field, 2022–25 | |
Rank 37; likely between #18 and #63 of 1,367Nature Reviews Drug DiscoveryNature Portfolio · United States | 4.25Q1 | 17.13 3.07 down from 2024 | 555 | 8% | — | ||
Rank 38; likely between #29 and #49 of 1,367Gut MicrobesOALandes Bioscience · United States | 4.21Q1 | 15.97 3.79 up from 2024 | 921 | 100% | $3,060 | Rising vs field, 2022–25 | |
Rank 39; likely between #22 and #60 of 1,367Journal of Biomedical ScienceOABioMed Central · Switzerland | 4.17Q1 | 15.16 1.64 up from 2024 | 298 | 100% | $0 listed | Rising vs field, 2022–25 | |
Rank 40; likely between #28 and #56 of 1,367Nature Ecology & EvolutionNature Portfolio · United Kingdom | 4.08Q1 | 10.83 1.36 up from 2024 | 883 | 44% | $12,690 | ||
Rank 41; likely between #23 and #63 of 1,367Nucleic Acids ResearchOAOxford University Press · United Kingdom | 4.04Q1 | 15.81 0.63 up from 2024 | 3,657 | 100% | $3,992 | ||
Rank 42; likely between #33 and #53 of 1,367TheranosticsOAIvyspring International Publisher · Australia | 4.04Q1 | 14.91 1.49 up from 2024 | 1,147 | 100% | $1,671 | Rising vs field, 2022–25 | |
Rank 43; likely between #27 and #62 of 1,367Medicinal Research ReviewsWiley · United States | 4.01Q1 | 14.50 1.49 up from 2024 | 181 | 46% | $4,980 | ||
Rank 44; likely between #29 and #63 of 1,367Cell Death and DifferentiationSpringer Nature · United Kingdom | 3.98Q1 | 13.27 2.42 down from 2024 | 497 | 92% | $5,790 | Rising vs field, 2022–25 | |
Rank 45; likely between #31 and #61 of 1,367Pharmacology & TherapeuticsElsevier BV · United States | 3.97Q1 | 14.05 1.78 up from 2024 | 394 | 46% | $5,660 | Rising vs field, 2022–25 | |
Rank 46; likely between #22 and #70 of 1,367Physiological ReviewsAmerican Physiological Society · United States | 3.95Q1 | 28.70 2.59 up from 2024 | 123 | 65% | — | ||
Rank 47; likely between #17 and #82 of 1,367MycosphereOAGuizhou Academy of Agricultural Sciences | 3.94Q1 | 11.80 1.48 up from 2024 | 83 | 100% | — | ||
Rank 48; likely between #32 and #61 of 1,367Nature AgingNature Portfolio · United States | 3.93Q1 | 14.49 2.66 up from 2024 | 558 | 46% | $12,690 | ||
Rank 49; likely between #40 and #53 of 1,367Science AdvancesOAAmerican Association for the Advancement of Science · United States | 3.91Q1 | 14.45 0.96 up from 2024 | 6,597 | 100% | $4,500 | ||
Rank 50; likely between #19 and #92 of 1,367Studies in MycologyElsevier BV · Netherlands | 3.85Q1 | 9.49 5.05 down from 2024 | 54 | 89% | $1,430 |
141 Biochemistry, Genetics and Molecular Biology journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
Full rising list for Biochemistry, Genetics and Molecular Biology
- 1Signal Transduction and Targeted TherapyOAMolecular Biology+217% vs groupOJR 4.84 → 14.09range +163% to +281%
- 2Crohn s & Colitis 360OAGenetics+171% vs groupOJR 0.41 → 1.02range +109% to +252%
- 3Chinese Herbal MedicinesOAMolecular Biology+144% vs groupOJR 0.91 → 2.05range +94% to +207%
- 4Current Molecular PharmacologyMolecular Biology+146% vs groupOJR 0.71 → 1.60range +82% to +231%
- 5ScienceMolecular Biology+89% vs groupOJR 4.27 → 7.42range +73% to +106%
- 6The BreastOACancer Research+202% vs groupOJR 0.72 → 2.00range +59% to +476%
- 7PhytomedicineMolecular Biology+63% vs groupOJR 2.00 → 3.01range +49% to +79%
- 8Cellular and Molecular NeurobiologyMolecular Biology+79% vs groupOJR 1.14 → 1.87range +49% to +116%
- 9Medizinische GenetikGenetics+168% vs groupOJR 0.15 → 0.36range +48% to +387%
- 10EBioMedicineOAMolecular Biology+59% vs groupOJR 2.21 → 3.24range +42% to +79%
- 11Molecules and CellsOAMolecular Biology+88% vs groupOJR 0.83 → 1.44range +41% to +150%
- 12Molecular Aspects of MedicineMolecular Biology+83% vs groupOJR 2.55 → 4.29range +37% to +145%
- 13Trends in Pharmacological SciencesMolecular Biology+73% vs groupOJR 1.08 → 1.72range +35% to +121%
- 14Redox BiologyOAMolecular Biology+50% vs groupOJR 3.19 → 4.39range +34% to +67%
- 15BiocellOAMolecular Biology+65% vs groupOJR 0.25 → 0.39range +34% to +105%
- 16Journal of NanobiotechnologyOAMolecular Biology+49% vs groupOJR 2.73 → 3.75range +33% to +67%
- 17Journal of the Canadian Association of GastroenterologyOAGenetics+107% vs groupOJR 0.55 → 1.05range +33% to +223%
- 18MicrobiologyOAMolecular Biology+78% vs groupOJR 0.80 → 1.30range +33% to +137%
- 19Cell Communication and SignalingOAMolecular Biology+65% vs groupOJR 2.13 → 3.22range +33% to +104%
- 20ToxiconGenetics+54% vs groupOJR 0.57 → 0.80range +32% to +80%
No-label zone, -9.1% to +10%Group median changeBar scale -84% to +528% (ratio scale)
136 Biochemistry, Genetics and Molecular Biology journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1Planta MedicaMolecular Biology-81% vs groupOJR 0.93 → 0.17range -85% to -76%
- 2Journal of Biomedical NanotechnologyMolecular Biology-79% vs groupOJR 0.67 → 0.13range -83% to -74%
- 3Stem Cell ResearchOAMolecular Biology-58% vs groupOJR 0.35 → 0.13range -65% to -50%
- 4F1000ResearchOAMolecular Biology-54% vs groupOJR 0.72 → 0.30range -60% to -48%
- 5Wellcome Open ResearchOAMolecular Biology-59% vs groupOJR 0.94 → 0.36range -70% to -45%
- 6Journal of Histochemistry & CytochemistryMolecular Biology-56% vs groupOJR 1.09 → 0.45range -69% to -37%
- 7Journal of OncologyMolecular Biology-45% vs groupOJR 1.12 → 0.57range -52% to -36%
- 8Evidence-based Complementary and Alternative MedicineMolecular Biology-38% vs groupOJR 0.93 → 0.53range -43% to -32%
- 9BioelectricityMolecular Biology-59% vs groupOJR 0.62 → 0.24range -75% to -32%
- 10eLifeOAMolecular Biology-35% vs groupOJR 2.26 → 1.36range -38% to -31%
- 11Materials ExpressMolecular Biology-43% vs groupOJR 0.23 → 0.12range -54% to -28%
- 12Stem Cells and DevelopmentMolecular Biology-45% vs groupOJR 1.15 → 0.58range -58% to -27%
- 13Journal of Biomolecular Structure and DynamicsMolecular Biology-30% vs groupOJR 1.07 → 0.69range -36% to -23%
- 14Eurasian Journal of Medicine and OncologyOAMolecular Biology-64% vs groupOJR 0.62 → 0.21range -83% to -23%
- 15Molecular Therapy — Nucleic AcidsOAMolecular Biology-31% vs groupOJR 2.04 → 1.29range -38% to -23%
- 16ACS Central ScienceOAMolecular Biology-32% vs groupOJR 3.90 → 2.43range -42% to -21%
- 17Disease MarkersMolecular Biology-30% vs groupOJR 0.85 → 0.54range -39% to -21%
- 18AgingMolecular Biology-26% vs groupOJR 1.43 → 0.97range -32% to -20%
- 19Nature GeneticsMolecular Biology-33% vs groupOJR 8.64 → 5.36range -43% to -20%
- 20Biological ChemistryMolecular Biology-34% vs groupOJR 0.96 → 0.58range -46% to -19%
No-label zone, -9.1% to +10%Group median changeBar scale -86% to +608% (ratio scale)
Subfields of Biochemistry, Genetics and Molecular Biology, compared.
- Molecular Biology1,152
- Genetics125
- Cancer Research29
- Cell Biology28
- Molecular Medicine12
- Biophysics10
- Clinical Biochemistry4
- Biochemistry3
- Structural Biology2
- Developmental Biology1
- Physiology1
- Aging0
- Biotechnology0
- Endocrinology0
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
212 additional Biochemistry, Genetics and Molecular Biology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 1,367
- Window papers (baseline)
- 768,613 +2.4% from indicator year 2022
- Median OJR
- 0.871 -2.2% from indicator year 2022
- Rising journals (2025)
- 141Comparison-group list (141)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 609 | 650 | 696 | 742 | 765 | 806 | 835 | 888 | 919 | 951 | 1,003 | 1,064 | 1,125 | 1,172 | 1,217 | 1,271 | 1,311 | 1,339 | 1,365 | 1,369 | 1,349 | 1,339 | 1,358 | 1,366 | 1,355 | 1,367 | |
| Window papers (baseline) | 310,927 | 335,262 | 354,210 | 375,343 | 388,415 | 415,247 | 441,606 | 472,036 | 497,712 | 532,780 | 565,943 | 595,190 | 615,359 | 631,115 | 652,778 | 672,042 | 683,714 | 684,441 | 678,826 | 679,352 | 690,127 | 717,801 | 750,552 | 768,440 | 764,327 | 768,613 | |
| Median OJR | 0.628 | 0.634 | 0.68 | 0.76 | 0.81 | 0.8465 | 0.872 | 0.894 | 0.921 | 0.95 | 0.98 | 1.03 | 1.02 | 0.990 | 0.986 | 0.97 | 0.96 | 0.93 | 0.925 | 0.915 | 0.912 | 0.90 | 0.890 | 0.8474 | 0.853 | 0.871 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 1.9% | 1,206 journals |
| Retracted papers per 1,000 | Pooled rate: 4.798 per 1,000 | 1,059 journals |
| Output growth | Median: -6.4% | 1,233 journals |
| Open access share | Median: 100.0% | 1,367 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,300 | 943 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 24.4% | 1,335 journals |
| Review share | Median: 0.3% | 1,367 journals |
| Articles-only OJR | Median: 0.87 | 1,336 journals |
| Uncited share | Median: 22.7% | 1,367 journals |
| Citation concentration | Median: 42.1% | 1,363 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.